Show simple item record

dc.contributor.authorScarisbrick, J.en
dc.contributor.authorQuerfeld, C.en
dc.contributor.authorAkilov, O.en
dc.contributor.authorBagot, M.en
dc.contributor.authorCórdoba, R.en
dc.contributor.authorCowan, Richarden
dc.contributor.authorGarcía-Sancho, A. M.en
dc.contributor.authorGeskin, L. J.en
dc.contributor.authorHuen, A. O.en
dc.contributor.authorJadwani, J.en
dc.contributor.authorLiu, Y.en
dc.contributor.authorZhao, H.en
dc.contributor.authorMorris, S.en
dc.contributor.authorOrtiz-Romero, P. L.en
dc.contributor.authorPatel, A.en
dc.contributor.authorPinter-Brown, L. C.en
dc.contributor.authorPujol, R. M.en
dc.contributor.authorQuaglino, P.en
dc.contributor.authorSaba, N. S.en
dc.contributor.authorVuppugalla, R.en
dc.contributor.authorKim, Y. H.en
dc.date.accessioned2025-02-03T10:25:17Z
dc.date.available2025-02-03T10:25:17Z
dc.date.issued2024en
dc.identifier.citationScarisbrick J, Querfeld C, Akilov O, Bagot M, Córdoba R, Cowan R, et al. Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S30-S1. PubMed PMID: WOS:001330761900064. English.en
dc.identifier.doi10.1016/j.ejca.2024.114402en
dc.identifier.urihttp://hdl.handle.net/10541/627377
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ejca.2024.114402en
dc.titlePreliminary results from an ongoing phase 2, open-label, multicenter, single-arm study assessing an every-4-week dosing schedule of mogamulizumab in patients with cutaneous t-cell lymphomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentChristie Hospital Foundation NHS Trust, University of Manchester, Manchester, United Kingdomen
dc.identifier.journalEuropean Journal of Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record